✦ LIBER ✦

A 22-week, multicenter, randomized, double-blind controlled trial ofCrocus sativusin the treatment of mild-to-moderate Alzheimer’s disease

✍ Scribed by Shahin Akhondzadeh; Mehdi Shafiee Sabet; Mohammad Hossein Harirchian; Mansoreh Togha; Hamed Cheraghmakani; Soodeh Razeghi; Seyyed Shamssedin Hejazi; Mohammad Hossein Yousefi; Roozbeh Alimardani; Amirhossein Jamshidi; Shams-Ali Rezazadeh; Aboulghasem Yousefi; Farhad Zare; Atbin Moradi; Ardalan Vossoughi

Book ID: 105882908
Publisher: Springer
Year: 2009
Tongue: English
Weight: 161 KB
Volume: 207
Category: Article
ISSN: 0033-3158
DOI: 10.1007/s00213-009-1706-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Saffron in the treatment of patients wit

Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial

✍ S. Akhondzadeh; M. Shafiee Sabet; M. H. Harirchian; M. Togha; H. Cheraghmakani; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Dehydroepiandrosterone treatment of wome

Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: A multicenter randomized, double-blind, placebo-controlled trial

✍ Deh-Ming Chang; Joung-Liang Lan; Hsiao-Yi Lin; Shue-Fen Luo 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB 👁 2 views

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease

✍ J. C. MANSFIELD; M. PARKES; A. B. HAWTHORNE; A. FORBES; C. S. J. PROBERT; R.C. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 563 KB

A 6-month, randomized, double-blind, pla

A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease

✍ D.P. Devanand; Gregory H. Pelton; Karine Cunqueiro; Harold A. Sackeim; Karen Mar 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB 👁 2 views

## Abstract ## Objective In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation. ## Methods In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of ha

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre

Donepezil for the symptomatic treatment

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

✍ Anne Whitehead; Carlos Perdomo; Raymond D. Pratt; Jacqueline Birks; Gordon K. Wi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 3 views

## Abstract ## Background The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD). ## Method A systematic review of individual patient data from Phase II and III do